Hurthle

Hürth·le

(hērt'lĕ),
Karl W., German histologist, 1860-1945. See: Hürthle cell, Hürthle cell adenoma, Hürthle cell carcinoma.
References in periodicals archive ?
National Institute for Health and Clinical Excellence (NICE) as a treatment for progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hurthle cell) in adults whose disease does not respond to radioactive iodine, in NICE's Final Appraisal Determination (FAD).
Papillary thyroid carcinoma and FVPTC have been reported in follicular adenoma, hyperplastic nodules, and Hurthle (oncocytic) cell adenomas.
Among the benign lesions which are histologically proved, Hurthle cell adenomas showed increased number and size of AgNORs, when compared to the other type of benign lesions.
In our study the most frequent was the category IV with 30/60 (50%) showing follicular neoplasm or showing a risk factor for a follicular neoplasm with specification for Hurthle cell (oncocytic) type.
El tumor de celulas de Hurthle debe su nombre al histologo aleman Karl Hurthle y fue citado por James Ewing en 1919 quien maximizo la difusion de este termino, usado exclusivamente para la neoplasia oncocitica tiroidea.
The overall tumor histology consisted of 97 papillary (4 of these had the Hurthle cell variant), 33 papillary-follicular, and 12 follicular tumors; 7 tumors were multifocal.
Cytopathology was reported as benign, indeterminate (follicular or Hurthle cell neoplasm), suspicious for malignancy, or malignant according to The Bethesda System for Reporting Thyroid Cytopathology.
Metastatic Hurthle cell carcinoma of the thyroid presenting as a breast lump: A case report.
The FTC has a variant called Hurthle Cell Carcinoma [50,51].
1,2) HLA-DR4 had also been associated with an increased risk of developing the other diseases that ran in our personal and/or family medical history: DCM, Hashimoto's thyroiditis, and Hurthle cell thyroid tumors.
FDG PET/CT is recommended in select cases for the assessment of the extent of disease in patients with Hurthle cell carcinomas.